PDC*line Pharma

Eric Halioua, President and CEO

April 13 | 3:45pm | Dark Horse Consulting Ballroom 

Liège, Belgium


Founded in 2014, PDC*line Pharma is a clinical-stage biotech company that develops an innovative class of cancer vaccines, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells. PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T cells and is synergistic with checkpoint inhibitors. The technology can be applied to any type of cancer. PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical. The company has a staff of 32, with an experienced management team. It has raised more than €52 million in equity and non-dilutive funding. PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in Asian countries, for the development and commercialization of the PDC*lung01. The deal is worth €108 million, plus tiered royalties on net sales.


By using this website you agree to accept our Privacy Policy and Terms & Conditions